Burkitt's lymphomas (BLs) acquire consistent point mutations in a conserved domain of Myc, Myc Box I. We report that the enhanced transforming activity of BL-associated Myc mutants can be uncoupled from loss of phosphorylation and increased protein stability. Furthermore, two different BL-associated Myc mutations induced similar gene expression profiles independently of T58 phosphorylation, and these profiles are dramatically different from MycWT. Nol5a/Nop56, which is required for ribosomal RNA methylation, was identified as a gene hyperactivated by the BL-associated Myc mutants. We show that Nol5a is necessary for Myc-induced cell transformation, enhances MycWT-induced cell transformation and increases the size of MycWT-induced tumors. Thus, Nol5a expands the link between Myc-induced regulation of nucleolar target genes, which are rate limiting for cell transformation and tumor growth.
INTRODUCTION
Burkitt's lymphoma (BL) is an aggressive mature B-cell lymphoma, 1 in which the Myc proto-oncogene is translocated to the immunoglobulin loci. 2 In addition to the consistent chromosomal translocations, a majority of BLs have mutations in the coding region of Myc, which cluster in a conserved region known as Myc Box I (MBI), including E39D, A44V, P57S, T58A and T58I. [3] [4] [5] [6] [7] [8] [9] The repeated identification of these mutations in tumors suggests that they are selected for during Myc-driven tumorigenesis. The majority of investigations into the activity of the BL Myc mutants have focused on MycT58A. [10] [11] [12] Myc is phosphorylated on T58, and this phosphorylation is reported to be required for Myc degradation. 13 MycT58A has been found to have an increased half-life and expression level, an increased transforming activity and/or an impairment in Myc-induced apoptosis. 10, [14] [15] [16] [17] [18] Studies in systems in which Myc does not induce apoptosis still show increases in transformation by MycT58A-expressing cells, 10, 14, 15 suggesting that changes in apoptosis are not solely responsible for changes in Myc oncogenic activity.
Myc likely drives cell proliferation through its broad influence on gene expression, which controls a number of essential functions; metabolism, protein synthesis, mRNA cap methylation and promoting the activity of RNA pol I and III. [19] [20] [21] [22] [23] [24] [25] The question arises whether the transformed phenotype induced by Myc overexpression is the result of a general increase in all Myc functions or due to altered regulation of specific genes. In cancers of several origins, it has been demonstrated that deregulation of specific Myc targets genes has an integral role in promoting the transformed phenotype. 19, 20 Studies on the effect of the T58A mutation on target gene regulation vary widely, but some specific examples of genes and proteins differentially expressed in response to MycWT and MycT58A expression have been found. 17, 26, 27 To date, there has been scant investigation of the more common BL-associated Myc mutants, MycE39D and MycT58I. 10, 28 In this study, we applied global gene expression analysis to examine how the BL-associated MBI mutants modulate Myc function and to identify the target genes that these mutants regulate to enhance Myc-induced transforming activity. We find that different mutations converge on remarkably similar and substantial changes in Myc-responsive genes compared with MycWT and that Nol5a/Nop56, a gene involved in ribosome biogenesis, may be a critical gene involved in Myc-mediated oncogenic transformation.
RESULTS

BL-associated Myc mutations increase the oncogenic potential of
Myc, independent of T58 phosphorylation To investigate the role of BL-associated Myc mutants in Myc-mediated tumorigenesis, we created a panel of mutants corresponding to the most common mutations; MycE39D, MycT58I and MycT58A. 10 Upon stable overexpression of these mutants, we observed variable levels of Myc expression ( Figure 1a ). The mutants MycE39D and MycT58I expressed similarly to Myc wild type, whereas MycT8A showed a substantial increase (2.6-fold) in expression compared with Myc wild type.
To determine whether the increase in expression was due to changes in protein stability, we treated the cells with cycloheximide and observed protein levels at varying times ( Figure 1b) . The half-life of MycE39D was equivalent to that of MycWT (23±6.2 min), similar to previously reported half-lives for Myc, whereas MycT58A had an increased half-live of more than twice that of MycWT (59.7 ± 10.4 min). This result is consistent with previous studies of MycT58A half-life.
29 Surprisingly, we did not observe any appreciable increase in MycT58I stability compared with that of MycWT, consistent with the equivalent steady-state level. We observed that MycWT and MycE39D retained T58 phosphorylation, whereas both the MycT58A and MycT58I mutation where no longer phosphorylated in both HEK293 and myc À / À fibroblasts ( Figure 1c and data not shown). One explanation for the differential stability of MycT58A versus MycT58I could be previously observed differences in S62 phosphorylation, 10 which contribute to changes in stability. 13 As the E39D and T58I mutations do not increase protein stability, we wanted to determine if these mutations were still able to enhance Myc-mediated transformation (Figure 1d ). Although we found no change in the proliferation rates ( Supplementary  Figure 1) , all three mutants (MycE39D, MycT58A and MycT58I) enhanced anchorage-independent growth compared with MycWT or the transformation-defective MycDMB2 mutant. We observed a 35-40% increase in Myc-mediated transformation on average. Thus, Myc-induced transformation is enhanced with BL-associated Myc mutants, independent of protein stability and T58 phosphorylation status. A previous study failed to show similar increases in these Myc mutant alleles. 10 However, these studies used an oncogene cooperation assay to determine oncogenic potential, which may lack the sensitivity to observe these more subtle qualitative difference from the more robust quantitative difference between c-Myc overexpression.
MycE39D and MycT58I regulate target gene expression similarly but significantly different from MycWT We investigated whether the enhanced transforming activity of the BL-associated Myc mutants could be correlated with differential regulation of target genes. To avoid contributions of differential protein stability, we transduced MycE39D, MycT58I and MycDMB2 (a non-transforming Myc mutant) into myc À / À fibroblasts. 30 Myc protein expression in this polyclonal cell system is relatively low, and MycE39D and MycT58I were expressed equivalently to MycWT and at physiological levels similar to parental myc þ / þ fibroblasts (Supplementary Figure 2a) . Proliferation rates and cell morphology were also similar to parental fibroblasts. RNA was harvested from two independent log-phase pools for each Myc variant or vector control and analyzed for gene expression by whole-genome microarray. A graphic comparison of gene expression profiles can be visualized by hierarchical clustering of the complete data set (Figure 2a ). After filtering and normalizing the data, the number of genes upregulated and downregulated by 1.5-, 1.75-and 2-fold in response to each Myc protein was compared with vector control (Supplementary Figure 2b) . Consistent with microarray data from this and other cell systems, expression of MycWT was found to regulate a large number of genes in a MB2-dependent manner, and there were generally equivalent numbers of genes upregulated and downregulated.
A key question was whether MycWT and the BL-associated mutants regulated the same or different genes. We carried out a 'Significance Analysis of Microarrays' or SAM, 31 which analyzes the (Figure 2b ). At a false discovery rate of 1% in a two-class analysis, SAM determined that there were 3326 genes differentially expressed between MycWT-expressing and vector control myc À / À cells. Similarly, 4494 genes were differentially expressed between MycE39D-expressing and vector control cells, and 4116 genes were differentially expressed between MycT58I-expressing and vector control cells. The most significant question is whether MycWT and the BL-associated Myc mutants activate the same or different genes. We made the unexpected finding that a large number of genes are differentially regulated by MycWT and the Myc mutants. Using the same 1% false discovery rate, there were 2150 genes differentially regulated between cells expressing MycWT and MycE39D, and 2186 genes between cells expressing MycWT and MycT58I (Supplementary Table 1 ). Most strikingly, there was little difference between the gene sets expressed in MycE39D and MycT58I. SAM determined that only 100 genes were expressed at a significantly different level between these BLassociated Myc mutants. As MycE39D is phosphorylated at both T58/S62, whereas MycT58I is not, this substantial shift in Mycresponsive genes is independent of phosphorylation status. Thus, two independent mutations skew the Myc response in a remarkably similar way from the MycWT profile, correlating with an enhanced oncogenic potential for both mutants.
We next examined the overlap of genes upregulated and downregulated 1.5-fold or more over vector in MycWT and BL-associated mutant gene sets (Figure 2c, Supplementary  Tables 2 and 3) . Of the 1222 genes activated by MycWT, 462 (38%) were activated by MycWT alone, whereas a nearly equivalent number (615; 50%) were jointly activated by the BLassociated mutants alone. Similarly, 164 of 919 (18%) genes were repressed by MycWT alone, whereas 521 (56%) were jointly repressed by BL-associated mutants alone. We noted that the total number of genes activated and repressed by MycE39D was greater (approximately 50%) than Myc T58I and MycWT. However, 1186 of 1345 (89%) were upregulated and 1092 of 1329 (82%) were downregulated similarly between MycT58I and MycE39D. We performed a gene ontology (GO) term analysis on these subsets of genes (MycWT only, BL-associated mutant only and commonly regulated) to determine whether any particular pathway changes could account for the observed increase in tumorigenesis. Although there were slight changes in gene numbers in a variety of pathways, we did not observe any significant changes in important pathways for the BL-associated mutants.
It is apparent that broad groups of genes are differentially regulated by the Myc mutants versus MycWT, and gene expression sometimes reversed from activated to repressed (or visa versa) between MycWT and mutants. This demonstrates that, although all the Myc proteins regulate a subset of the same genes, there are large groups of genes that are regulated differently by the Myc mutants and MycWT. We also noted that the MycE39D responsive genes have generally more robust signals than MycT58I, consistent with the larger number of genes that pass each threshold. transcription by binding to target genes and recruiting histone acetyltransferase complexes. 12, 32, 33 We investigated Myc recruitment and histone acetylation on two genes, HSP60 and Nucleolin, which are hyperactivated by the Myc mutants compared with MycWT. These were compared with two genes, CAD and NME1, which had reduced activation by the Myc mutants compared with MycWT. We used independent RNA samples to confirm differential expression by the Myc mutants compared with MycWT (Figure 3a) . CAD and NME1 were induced more by MycWT than the Myc mutants, whereas HSP60 and Nucleolin were induced more by the Myc mutants. For all four genes, we used chromatin immunoprecipitation (ChIP) to investigate Myc recruitment to the E-box closest to the transcription initiation site (Figure 3b ). We found that MycWT, MycE39D and MycT58I were all recruited equivalently to the E-boxes of all four Myc target genes. As a negative control, we found that the Myc proteins were not significantly recruited to the b-globin promoter (data not shown). We next investigated histone acetylation in response to MycWT and the Myc mutants at the same genes. We found Mycdependent histone H4 acetylation at all four target genes ( Figure 3c ). In correlation with the increased HSP60 and Nucleolin expression, we observed increased H4 acetylation at the HSP60 and NUCL genes in response to expression of the Myc mutants compared with that induced by MycWT. Conversely, in correlation with the reduced CAD and NME1 expression observed in response to MycE39D and MycT58I, we observed reduced histone acetylation at the CAD and NME1 genes compared with that induced by MycWT. Thus, the Myc mutations affect local chromatin modifications but do not affect promoter occupancy, consistent with their location in the Myc transactivation domain and not the DNA-binding domain.
Myc mutations differentially regulate Nol5a, a gene required for ribosome biogenesis The BL-associated mutations result in increased Myc-induced cell transformation and a qualitative change in Myc responsive genes. We wanted to test the hypothesis that the increase in cell transformation was a result of specific changes in gene expression. Myc regulates all aspects of protein synthesis and ribosome biogenesis, 34, 35 and recent evidence suggests that ribosome biogenesis may be a primordial function of Myc, conserved throughout evolution in even the most primitive organisms that harbor Myc and Max orthologs. 36 Furthermore, mice that overexpress Myc but express only one functional copy of ribosomal protein L24 have significantly reduced translation rates and impaired Myc-mediated oncogenesis. 37 We therefore focused our studies on an essential ribosome biogenesis target gene that was differentially activated in Myc mutants and is used as a molecular diagnostic for BL.
38 Nol5a (nucleolar protein 5a/ Nop56) encodes a component of an ribosomal RNA (rRNA) methylation complex that also regulates rRNA processing. [39] [40] [41] We first established that Nol5a expression was also increased in Nol5a overexpression is required for Myc-mediated transformation To explore a functional role for Nol5a in Myc transformation, Nol5a expression was carefully titrated using small interfering RNAs (siRNAs). As expected, nearly complete depletion of Nol5a expression resulted in severely reduced proliferation rates and increased cell death (not shown), consistent with its essential role in ribosome biogenesis. [39] [40] [41] However, when levels of Nol5a were reduced by 50% in Rat1a/Myc cells, equivalent to levels in cells not overexpressing Myc, proliferation rates were unaffected and cells remained viable (Figure 5a and Supplementary Figure 3) . We next examined how the reduction of Nol5a expression would affect the transformation potential of MycWT, MycE39D and MycT58I. Soft agar colony growth confirmed a substantial increase in transformation in cells overexpressing MycWT, MycE39D and MycT58I. Upon depletion of Nol5a, there was significant loss in transformation (Figure 5b) . In summary, cell transformation by Myc is dependent on Myc-induced Nol5a expression, whereas a maximal cell proliferation rate only requires vector control levels of Nol5a expression.
Nol5a enhances MycWT-induced transformation and tumor growth Expression of the Myc mutants increases Nol5a expression to a level above that induced by MycWT. We wanted to investigate whether this hyperactivation had functional significance. To this end, we experimentally increased Nol5a levels above those found in MycWT-expressing cells by ectopically expressing Nol5a in MycWT/Rat1a cells. We confirmed that ectopic expression of Nol5a did not enhance endogenous or exogenous MycWT expression (Figure 6a ). Cells were plated in soft agar, and colonies were counted and measured ( Figure 6b ). As described earlier, expression of MycWT allowed cells to grow into robust colonies in soft agar. We found that further increasing the expression of Nol5a in MycWT-expressing cells enhanced cell transformation, producing significantly larger colonies, as depicted in colony images and diameter measurements (Figures 6b and c) . Increased Nol5a expression alone was not sufficient to permit cell growth in soft agar (Figure 6b ). The increased colony size was not due to any increase in the cell proliferation rate of cells expressing MycWT and elevated Nol5a (Supplementary Figure 3b) or in rRNA processing (Supplementary Figure 4) . In summary, expression of Nol5a at levels above those induced by MycWT, as found in response to the BL-associated Myc mutants, is functionally significant and can enhance MycWT-induced cell transformation.
As Nol5a expression enhances MycWT-induced cell transformation in the soft agar assay, we wanted to expand upon these assays and measure in vivo tumor growth. We injected Rat1a cells expressing MycWT, MycWT plus Nol5a or vector control subcutaneously into the flanks of nude mice (Figures 6d and e) . Vector control injections resulted in no tumors or nearly undetectable tumors (0.1 g or below), whereas all mice injected with cells expressing MycWT or MycWT and Nol5a produced sizeable tumors. We compared the mean mass of each of the groups, 1.20 and 2.14 g, respectively, and determined that the mass of MycWT/Nol5a tumors was significantly higher than those produced from MycWT (P-value 40.001). Therefore, Nol5a enhances Myc-induced tumor formation similarly to oncogenic transformation assays in cell culture.
DISCUSSION
We have been interested in a detailed understanding of how BL-associated Myc mutations contribute to cancer. The most frequently studied mutation has been MycT58A, which can have a modest effect on Myc protein levels through reduced turnover. However, we show that BL-associated mutations enhance cell transformation independently of loss of T58 phosphorylation or increases in Myc expression. All Myc mutants investigated have increased soft agar colony size. Thus, the effect of T58 mutations appear to be allele-specific, with some leading to increased half-life and others unchanged from MycWT. These observations are consistent with previous findings that Myc mutations do not alter Myc protein levels in a murine B-lymphoma model. 17 Thus, the mutations contribute to qualitative rather than quantitative changes in Myc protein biochemistry and activity.
To understand how the BL-associated Myc mutants increase cell transformation, we used expression microarrays to investigate the endogenous gene response to these mutants. We focused our study on MycE39D, which retains T58 phosphorylation, and on MycT58I, which lacks the T58 phosphorylation site, to determine whether this phosphorylation status qualitatively effected target gene expression. We found that the MycE39D mutation increases the number of Myc target genes by approximately 50%, but the T58I mutation had no effect on the absolute number of activated or repressed genes at each threshold. Therefore, a global increase or decrease in gene expression is not necessary for increased cell transformation. However, analysis of the transcriptome of MycE39D and MycT58I-expressing cells revealed that these point mutants had a significant effect on the profile of responsive genes compared with MycWT. From gene clustering and SAM analysis, MycWT, MycE39D and MycT58I were found to regulate a subset of the same genes, but a large proportion of the BL-associated Myc mutant responsive genes are significantly different from those regulated by MycWT. The surprising finding was that MycE39D and MycT58I converge to regulate an almost identical set of target genes that is distinct from MycWT. Thus, in this system, subtle mutations in the Myc transactivation domain substantially alter the responsive genes, and blocking T58 phosphorylation is not responsible for altering the Myc transcriptome. Recent publications suggest a model for Myc function as a 'transcriptional amplifier' of all active genes in a cell. 42, 43 Although this model can account for the broad effect that Myc has on genome-wide transcription, it does not account for the allele-specific differences in individual gene expression quantitated in our study.
Myc promotes increased transcription by increasing histone acetylation at target gene promoters. 12, 32, 33 To gain insight into the mechanism by which the BL-associated point mutations were altering the Myc transcriptome, we investigated Myc recruitment and histone acetylation at four well-established Myc target genes. The BL-associated mutations did not influence Myc recruitment to the genes tested, but we found significant changes in histone acetylation that paralleled changes in mRNA levels. We suggest that the BL-associated mutations induce similar conformational changes in the Myc transactivation domain from that of MycWT, which results in altered recruitment of chromatin-modifying and transcription-promoting complexes.
We found that over 2000 genes were differentially regulated between MycWT and the Myc mutants. Although it is possible that many of these genes are collectively responsible for the increased transforming activity of the mutants, we focused our attention on a single differentially regulated gene, Nol5a/Nop56. Nol5a is a nucleolar protein that is a component of a ribonuclear protein complex, which methylates rRNA and regulates rRNA processing, although it may also have other functions. [39] [40] [41] Our attention was drawn to Nol5a because its expression has been found to be highly associated with BL and serves as a molecular marker for diagnosis, 38 suggesting a potentially biological role for its differential expression in these tumors. In addition, Nol5a has been shown to be upregulated in two additional B-cell lymphomas, diffuse B-cell lymphoma and chronic lymphocytic leukemia. 44, 45 Nol5a has previously been found to be a Myc-target gene by several global analyses of gene expression, including in B cells. [46] [47] [48] [49] We show that Nol5a expression is also high in BL cell lines and induced in response to expression of MycWT in B cells and in fibroblasts. Nol5a is further increased by the MycE39D and MycT58I mutations. The higher levels of Nol5a expression induced by MycE39D and MycT58I, above that induced by MycWT, is functionally significant because it enhanced MycWTinduced transformation in two different assays. This demonstrates that increased Nol5a expression by the BL-associated Myc mutants is critical for enhanced oncogenicity.
Nol5a is an essential gene for cell viability, and it has been demonstrated to be rate limiting for cell proliferation in yeast and mammalian cells. 39, 50 Notably, a screen for genes that promote a shortened G1 phase of the cell cycle in yeast identified Nop56/ Sik1 as an important mediator of cell cycle progression. 51 We also found that severe Nol5a depletion inhibited cell proliferation. However, when we titrated the levels of Nol5a in Myc-expressing cells to levels found in vector control cells, cell transformation was inhibited but there was no effect on cell proliferation. Therefore, Nol5a is rate limiting for biological effects over a broad range of expression. A basal level of Nol5a is necessary and sufficient for cell proliferation; however, the MycWT-induced increase in Nol5a is necessary for cell transformation, and further Nol5a increases enhance cell transformation. Nol5a joins the emerging group of nucleolar proteins, which are essential for ribosome biogenesis and which have also been found to promote cell transformation and tumorigenesis. 52, 53 Myc proteins are recognized to regulate expression of a large number of genes involved in ribosome biogenesis 47, [54] [55] [56] including NPM1 57 and DKC1, 58 as well as rRNA synthesis itself. 19 Furthermore, ribosome biogenesis is the only cellular process in which the genes harbor conserved Myc/Max-binding sites from primitive metazoans to humans. 36 Although the only known function of Nol5a is in ribosome biogenesis, it may also have an extraribosomal function that remains to be discovered. 59 Nucleophosmin, which is frequently mutated in human cancer, offers a precedent for a novel non-nucleolar function as it is essential for ribosome biogenesis but also has a number of additional roles including regulating the activity and stability of Myc, p53 and ARF, and in centrosome duplication. 57, 60 Nevertheless, the activity of Nol5a in oncogenic transformation strengthens the link between Myc overexpression and ribosome biogenesis and suggests that the protein synthetic capacity of cancer cells may be crucial for Myc-induced tumor formation.
MATERIALS AND METHODS
Cell culture and stable transfections
Rat1a fibroblast, myc À / À fibroblast (HO15.19) 30 and retroviral packaging Phoenix cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. BL lines were maintained in Iscove's modified dulbecco's medium (IMDM)/10% fetal bovine serum. c-Myc repressible P493-6 cells were maintained in RPMI/ 10% fetal bovine serum and exogenous c-Myc was repressed by treatment with 0.1 mg/ml tetracycline for 72 h. Retroviral expression of HO15.19 and Rat1a cells was performed using Phoenix retroviral transduction system.
Western blots and immunoprecipitation
Rat1a fibroblast, myc À / À fibroblast and BL cell lines were lysed in F-buffer (10 mM Tris pH 7.05, 50 mM NaCl, 30 mM Na pyrophosphate, 5 mM ZnCl, 10% glycerol, 0.1% Triton). Cell extracts were normalized for protein content and either immunoprecipitated or whole-cell lysates run for western blotting analysis. Myc was immunoprecipitated in HO cells using either monoclonal anti-Myc (C33, Santa Cruz, Santa Cruz, CA, USA) or anti-pyo (AFC-115P, Covance, Denver, PA, USA), and western blots performed with polyclonal anti-Myc (N262, Santa Cruz) for total Myc. To determine the T58 phosphorylation status, 293 cells were transiently transfected, lysed in RIPA Protein stability c-Myc expressing myc À / À cells were treated with cycloheximide for up to 120 min. Cells were then lysed using F-buffer, immunoprecipitated and blotted as described above. Band intensity was determined by ImageJ image processing software. Results are from two independent experiments.
Real-time PCR
Reverse transcription-PCR was performed using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) according to manufacturer's instructions. For each experiment, RNA from two independently established cell lines was analyzed. Quantitative PCR was performed by mixing complementary DNA, appropriate primers and iQ SYBR Green Supermix (Bio-Rad) and analyzed on a C1000 Thermal Cycler (Bio-Rad). Data were analyzed using Bio-Rad CFX Manager 2.0 software. Error bars (s.d.) represent three biological replicates and significance was determined using Student's t-test.
ChIP
ChIPs were performed using the Upstate Chip kit (Millipore, Billerica, MA, USA). The following antibodies were used: polyclonal anti-Myc (N-262; Santa Cruz), anti-Acetyl-H4 (Upstate) and control IgG (Santa Cruz). Error bars (s.d.) represent three biological replicates and significance was determined using Student's t-test.
Transformation assays
Soft agar assays were performed as described in Cowling et al. 61 Seven days after plating, the longest diameter of 100 colonies from duplicate wells was measured using a reticule. After pretreated with Nol5a or control siRNA, 100 colonies per well from duplicate wells were measured 3 days after plating, and the size (mm) of colonies over three reticule divisions (75 mm) in diameter were recorded. Differences in colony size are represented by percentage of colonies greater than 125 mm. Assays were repeated in duplicate wells over three independent experiments with similar results. Significance was determined using Student's t-test.
Microarrays
RNA was harvested on two independent occasions from two independent cultures of myc-null fibroblasts expressing vector control, MycWT, MycDMBII, MycE39D and MycT58I using Trizol, followed by phenol chloroform extraction. RNA integrity and concentration was verified by gel electrophoresis. RNA was analyzed on Agilent 4 Â 44K Whole Rat genome microarrays as described in Cowling et al. 61 RNA was labeled using the oligo-dT primed linear-amplification protocol according to manufacturer's instructions. Only genes with a signal 50% above background and with at least 70% good data across the arrays were considered for further analysis. The data were centered to the average of the two independent vector-only arrays and filtered for average changes in signal for either MycWT or Myc mutants that were above the threshold indicated.
Supervised SAM analysis, GO term analysis and Student's t-tests SAM 31 was performed using MeV 4.0 software (Dana-Farber Cancer Institute, Boston, MA, USA). To identify the genes that are most significantly different between the different cell types, we employed two-class SAM analysis with a false discovery rate of 1%. Only those clones in which both replicate spots were found significant were selected. GO term analysis (David, NIAID) was performed on genes upregulated 1.5-fold over vector for subsets representing MycWT only, BL-associated mutants only or commonly regulated genes. All other statistical significance was determined using non-paired Student's t-test with Graphpad Prism 6.0b (Graphpad, La Jolla, CA, USA).
Tumorigenicity assay 1 Â 10 6 cells in 100 ml phosphate-buffered saline were injected subcutaneously in the flanks of 6-week-old female nude mice (Charles River Laboratories, Wilmington, MA, USA) N ¼ 10 for all cell types injected. Tumors were excised after 3 weeks and weighed and measured. Significance in mean tumor volume was determined using Student's t-test.
